Mechanism of action of foscarnet against viral polymerases.
about
Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsInhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcriptionAlkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistanceCharacterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.Medical and virological aspects of ocular human immunodeficiency virus infection for the ophthalmologist.Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.Development of new antivirals for herpesviruses.Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Molecular mutagenesis of ppGpp: turning a RelA activator into an inhibitorOral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1.Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions.Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeuticsThe genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.DNA polymerases as therapeutic targetsPolyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor.The search for new therapies for human cytomegalovirus infections.Drug-induced alterations in Mg2+ homoeostasis.Anti-herpesvirus agents: a patent and literature review (2003 to present).KSHV targeted therapy: an update on inhibitors of viral lytic replication.Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.Loss of DNA methylation in zebrafish embryos activates retrotransposons to trigger antiviral signaling.Fulminant hepatic failure secondary to acyclovir-resistant herpes simplex virus.Review: Present and future directions in the treatment of chronic hepatitis B infection.Effects of Acyclovir, Foscarnet, and Ribonucleotides on Herpes Simplex Virus-1 DNA Polymerase: Mechanistic Insights and a Novel Mechanism for Preventing Stable Incorporation of Ribonucleotides into DNA.Inhibition of fosfomycin resistance protein FosA by phosphonoformate (foscarnet) in multidrug-resistant Gram-negative pathogens.Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.In search for effective and definitive treatment of herpes simplex virus type 1 (HSV-1) infectionsPhotodynamic Inactivation of Herpes Simplex Viruses
P2860
Q24537618-B9B1DFDB-C4CF-4FC3-BB93-A0BBF099C518Q28069489-6D507FB6-C577-4829-B670-E54972A8E2B5Q28359887-F2DE4DBB-52D4-4B1E-9252-81B2368D67F0Q28365182-9DB1CF71-0602-4266-B71B-30C1925AD643Q30363200-1AEA7965-CB4E-4128-BE54-53B638152954Q33569593-4B487425-2227-475A-91B1-AB0A708958B2Q34996622-F82BD863-A16D-4C80-8DDA-493ECF3EAE2CQ35669533-FC6D9E7B-4FBA-4AC3-8925-951ABEE50756Q35870930-88ADF54C-5DD7-4861-B52A-2A878B12DEDEQ35917530-B19FD489-DDF0-42BB-AFE3-C94506253F7DQ36269018-626FBBEE-7E1F-4DB6-8B6B-AEA55C486275Q36478736-A55BFAF8-9D1A-4AE9-97F5-398F3419AFA9Q36650823-1D6B41B6-314B-46FC-989F-A27EDD0F0257Q36673242-F7BB42E1-E1D2-4565-BD93-DC56D72FC200Q36866689-318BD5D2-5F6D-46E0-B3F5-694708B7E70DQ37173390-EB320BB0-7686-47D0-B210-C19F12D4FF20Q37216862-D4E4CC48-E8E7-4145-8B9A-070E9394D1C8Q37537503-47EF6F38-F80F-4EE6-897A-F32D6F79DC33Q37811458-4F80ABF6-3EA3-47A2-B1C1-D110F1F972E9Q37992700-5A681363-EC83-4CE3-9962-E1EA7EE955F5Q38228015-D54D9137-4F19-4206-8498-4D69C85B6139Q38271135-E8352642-4E23-4A89-88D5-072DB14CEA49Q38612672-BDDA99F1-9687-4D6C-BEE5-F9F0F6273C1BQ39474633-9D9BA39D-9EE5-497D-9484-116AFB3D7A2CQ40126784-54F914DC-6771-468D-856C-65A7C2F6A39AQ40501484-603E1012-E141-43BA-9B1E-202081FA68A9Q40866538-9A8ED4AC-56EE-428E-BBDB-A1CDF63F2DB2Q40935975-2A2C852E-C839-4F20-A420-C8738423AD52Q41989392-2C195F87-C54A-4453-B453-8849EF2F95D6Q44742776-563B37EA-E94D-48BB-815D-DC38D08BBED9Q56789970-F177B02C-9243-4271-9160-C71F98062D77Q57065815-092B89F4-F640-4895-839A-21D8B83181B1
P2860
Mechanism of action of foscarnet against viral polymerases.
description
1992 nî lūn-bûn
@nan
1992 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Mechanism of action of foscarnet against viral polymerases.
@ast
Mechanism of action of foscarnet against viral polymerases.
@en
type
label
Mechanism of action of foscarnet against viral polymerases.
@ast
Mechanism of action of foscarnet against viral polymerases.
@en
prefLabel
Mechanism of action of foscarnet against viral polymerases.
@ast
Mechanism of action of foscarnet against viral polymerases.
@en
P1476
Mechanism of action of foscarnet against viral polymerases.
@en
P2093
Crumpacker CS
P356
10.1016/0002-9343(92)90329-A
P407
P577
1992-02-01T00:00:00Z